8-K
filed July 3, 2023, 7:59 PM ET
ticker ALDX
CIK 0001341235
other material
confidence high
sentiment neutral
materiality 0.15
Aldeyra shareholders elect Brady and Joyce as Class III directors, approve 2023 equity plan
Aldeyra Therapeutics, Inc.
- Director Todd C. Brady reelected with 21,007,679 votes for, 7,405,955 withheld.
- Director Martin J. Joyce elected with 16,126,225 votes for, 12,287,409 withheld.
- Ratification of BDO USA as auditor approved: 43,474,045 for, 25,820 against.
- Advisory vote on executive compensation approved: 27,710,251 for, 57,323 abstain.
- 2023 Equity Incentive Plan approved: 27,066,030 for, 1,293,014 against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aldeyra Therapeutics, Inc. shareholders approved Election of two directors to serve as Class III directors until the Company’s 2026 annual meeting at the 2023-06-30 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-30
Exact text from the filing
Proposal 1: Election of Directors. The Company’s stockholders elected the following directors to serve as Class III directors until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Todd C. Brady, M.D., Ph.D. 21,007,679 7,405,955 15,106,765 Martin J. Joyce, M.B.A. 16,126,225 12,287,409 15,106,765
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aldeyra Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-30 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-30
Exact text from the filing
Proposal 2: Ratification of Appointment of BDO USA, LLP. The Company’s stockholders ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining 43,474,045 25,820 20,534
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aldeyra Therapeutics, Inc. shareholders approved Approval of the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan at the 2023-06-30 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-30
Exact text from the filing
Proposal 4: Approval of the Adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan. The Company’s stockholders approved the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 27,066,030 1,293,014 54,590 15,106,765
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aldeyra Therapeutics, Inc. shareholders approved Non-binding, advisory vote on the compensation of the Company’s named executive officers at the 2023-06-30 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-30
Exact text from the filing
Proposal 3: Advisory Vote on Executive Compensation. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 27,710,251 646,060 57,323 15,106,765
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.